Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

strategies

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

- PMLiVE

UK agrees comms strategy for potential flu pandemic

Publication draws lessons from 2009 swine flu pandemic

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Novo launches haemophilia tracking app

Will compete with similar apps from Pfizer, Baxter

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

- PMLiVE

Novo Nordisk posts ‘robust’ gains in sales and earnings

Diabetes drug Victoza and insulin analogue portfolio see strong growth

- PMLiVE

Novo wins CHMP backing for Tresiba and diabetes first

EMA advisors recommend approval of once-daily at unique higher strength

- PMLiVE

Novo Nordisk files new haemophilia drug in EU, US

Seeks approval for turoctocog alfa shortly after vatreptacog alfa pulled

- PMLiVE

Novo drops late-stage haemophilia candidate vatreptacog alfa

Patients developed anti-drug antibodies during phase III clinical trial

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links